<DOC>
	<DOCNO>NCT00197067</DOCNO>
	<brief_summary>GSK Biologicals develop partnership Malaria Vaccine Initiative PATH candidate malaria vaccine RTS , S/AS02 routine immunization infant child live malaria endemic area . The vaccine would offer protection malaria disease due parasite Plasmodium falciparum also would provide protection infection hepatitis B virus . Studies conduct use formulation RTS , S/AS02A ( 0.25 ml dose ) child adult show safe . Currently intramuscular vaccine EPI schedule administer dose volume 0.5 ml context , new variant RTS , S/AS02D ( 0.5 ml dose ) formulation compose active constituent quantities 0.25 ml dose RTS , S/AS02A . In study , RTS , S/AS02D ( 0.5 ml dose ) compare exist formulation , RTS , S/AS02A ( 0.25 ml dose ) .</brief_summary>
	<brief_title>A Study Evaluate Safety Immunogenicity GSK Biologicals ' Candidate Vaccines RTS , S/AS02D ( 0.5 mL Dose ) RTS , S/AS02A ( 0.25 mL Dose ) Administered IM According 0 , 1 , 2 Month Vaccination Schedule Children Aged 3 5 Years Living Malaria-endemic Region Mozambique .</brief_title>
	<detailed_description>Children participate study either receive RTS , S/AS02D ( 0.5 ml dose ) RTS , S/AS02A ( 0.25 ml dose ) intramuscularly accord 0 , 1 , 2 month schedule . The child followed-up throughout study period record safety event . Blood sample collect defined time point assess subject 's immune response relevant immunological indicator .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<criteria>Inclusion criterion : Healthy child sex age 3 5 year ( include 6th birthday ) previously immunize hepatitis B vaccine , whose parent guardians investigator believe could would comply requirement protocol , whose parent guardian would give write oral , sign thumb print witness informed consent , free obvious health problem establish medical history clinical examination enter study available foreseen duration immunization followup period . Exclusion criterion : If child find major congenital defect serious chronic illness ; history surgical splenectomy ; diagnosis clinical suspicion immunosuppressive immunodeficient condition ; family history congenital hereditary immunodeficiency ; history allergic disease reaction likely exacerbate component vaccine ; previous vaccination hepatitis B vaccine experimental vaccine ; child simultaneously participate clinical trial , child would exclude study .</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>5 Years</maximum_age>
	<verification_date>September 2011</verification_date>
</DOC>